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6yketheL The purpose of this study was to assess the effect of
andarrhythmic drugs on the timing of arrhythmic death .
Background. Sudden cardiac death remains a problem of
epidemic proportions. Delineating its pathophysiology is an im-
portant step in devising preventive measures . Previous studies
have shown a circadian pattern of onset of sudden cardiac death .
The effect of antiarrhythmic drugs on this pattern has not been
systematically studied .
Methods. The Cardiac Arrhythmia Suppression Trial (CAST)
was a multicenter double-blind, placebo-controlled study designed
to determine whether suppression of ventricular ectopic activity
by means of antiarrhythmic drugs (encainide, fiecainide or mor-
leizine) after acute myocardial infarction would reduce the inci-
dence of arrhythmic death .
The Cardiac Arrhythmia Suppression Trial (CAST) was
designed to test the hypothesis that suppression of unsus-
tained ventricular arrhythmias by antiarrhythmic drugs in
survivors of acute myocardial infarction would reduce the
incidence of arrhythmic death . The findings have been
reported elsewhere (1-3). Briefly, the incidence of arrhyth-
mic death was increased in the active treatment group
(compared with the placebo group) with all three drugs being
tested. This relation achieved statistical significance with
encainide and flecainide and in the short-term exposure
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Results . The trial was terminated prematurely because of an
unexpectedly high mortality rate in the active treatment group .
The onset of arrhythmic death in this group (in patients not
receiving beta-adrenergic blocking agents) displayed a bimodal
variation, with significant peaks in midmorning and late after-
noon/early evening. More than half of the symptomatic events
were accompanied by aaginalike symptoms. Approximately 30%
of all events occurred within 2 h of awakening .
Conclusions . Our data suggest the possibility of a complex
interaction among antiarrhythmic drugs, sympathetic nervous
system activation and acute myocardial ischemia. Planning of
future antiorrhythmic drug trials will need to take this informa-
tion into account .
(J Am Coll Cardiol 1994,23.2834)
phase of the study with moricizine and was trending unfa-
vorably in the long-term follow-up phase with moricizine
when the trial was terminated or, the recommendation of the
Data and Safety Monitoring Board . Although the fatal events
were presumably due to a drug-induced proarrhythmic ef-
fect, there is little direct electrocardiographic (BCC) infor-
mation about event initiation . Thus, the exact mechanism of
death in most patients is unknown .
Analysis of the temporal distribution of acute cardiovas-
cular events may be helpful in elucidating their pathophysi-
ology . Previous studies have demonstrated circadian
rhythms in the onset of sudden cardiac death, acute myo-
cardial infarction, transient myocardial ischemia, thrombotic
stroke and fatal pulmonary thromboembolism (4-13). In
each instance, the largest number of events occur in the
midmorning, although in some, a secondary peak in the late
afternoon and early evening has also been described (7,8) .
Recent studies have documented the relation between the
time of awakening and the onset of acute myocardial infarc-
tion and sudden cardiac death (13,14) . It has been theorized
that increased sympathetic tone associated with awakening
and assuming the upright posture may play a role . This
theory is reinforced by the finding that beta-adrenergic
blocking agents prevent or blunt the midmorning peak (6,7).
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The pathogenesis of the late afternoon/early evening peak is
less clear.
The present study reports the results of a CAST sub-
study, designed prospectively to test the hypothesis that the
circadian variation in the time of onset of out of hospital
arrhythmic death would be altered by antiarrhythmic drugs .
It differs from previous studies in that all events occurred in
patients who were either receiving carefully monitored ti-
trated doses of antianhythmic drugs or had been randomized
to receive the dose which had suppressed their ventricular
ectopic activity (by protocol definition) .
Methods
The institutional committee on human research approved
the study protocol in all participating institutions, and in-
formed consent was obtained from all subjects. A detailed
description of the CAST methodology has been provided
elsewhere (1-3) . The initial part of the trial (CAST I), in
which encainide, fiecainide and moricizine were used, was
begun on June 13, 1987 and terminated on April 18, 1989 with
respect to encainide or fiecainide. In CAST II, a third dose of
moricizine was added for new subjects and was terminated
on August 1, 1991 . The following is a brief review of the
more important aspects of the trial and more detailed infor-
mation in the areas relevant to the present analysis .
Patient population . Patients <80 years of age were eligi-
ble if they demonstrated an average of a6 ventricular
premature depolarizations/h on baseline 24-h ambulatory
ECG (Hotter) monitoring and had an ejection fraction X55%
within 90 days or s40%® within 2 years of an acute myocar-
dial infarction .
la titration in CAST I . All patients underwent
open label titration during which up to two oral doses of
three drugs (encainide, fiecainide and moricizine) were eval-
uated. Titration was stopped as soon as a drug and dose were
found that produced 4 reduction of ventricular prema-
ture depolarizations and X90% reduction of runs of unsus-
tained ventricular tachycardia as measured by 24-hr ECG
monitoring. Patients whose arrhythmia increased or who
were intolerant of all drugs were not advanced to the
randomized phase of the trial .
g d in CAST II . In CAST 11, patients recruited
after April 19, 1' ' were eligible for the study 4 to 90 days
after acute myocardial infarction by the same Hotter ECG
criteria as in CAST I and if left ventricular ejection fraction
was :540%.
Patients were randomized to receive either low dose
moricizine or matching placebo for a 2-week period . This
initial blinded phase evaluated only the 1st 2 weeks of
therapy. Subsequently, therapy was unblinded, and patients
who had been treated with active medication were evaluated
by Holter monitoring for suppression of ventricular ectopy .
Patients treated with placebo began active moricizine ther-
apy and were subsequently evaluated by Holter monitoring .
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Adequate suppression of ventricular ectopic activity was
defined as in CAST I .
Randomization and follow-up. Qualifying patients were
randomized to receive the drug dose that suppressed their
ectopic activity or to receive matching placebo in a double-
blind manner. Patients were seen during follow-up at
4-month intervals.
Mortality investigation . Deaths during open label,
blinded titration and the double-blind randomized aspect of
the study were investigated by the clinical center personnel,
who completed detailed death and cardiac arrest forms .
Information obtained included the timing of symptom onset,
the time of awakening on the day of death, concurrent
medication and the nature (e .g., anginalike, arrhythmic) of
acute symptoms . All information was accompanied by a
narrative summary by the local principal investigator, as
well as relevant notes from paramedical personnel, emer-
gency rooms, inpatient records and autopsy reports . Each
death was initially categorized locally and then reviewed and
coded in blinded manner by a central events committee . In
the event of disagreement between the local principal inves-
tigator and the events committee member (this occurred in
only 14% of cases), the death was classified by the entire
committee . This procedure was based on the experience
with classifying deaths in the Cardiac Arrhythmia Pilot
Study (15).
Study design. The CAST primary end point (arrhythmic
death or cardiac arrest) included witnessed instantaneous
death, unwitnessed death with no preceding change in
symptoms and for which no other cause could be ascribed,
resuscitated cardiac arrest, or witnessed death with angina-
like symptoms or symptoms suggestive of a cardiac arrhyth-
mia (e.g., syncope, palpitation or dizziness) in the absence of
severe congestive heart failure or shock . Events classified as
arrhythmic that began outside a hospital or in the emergency
room and that occurred in any phase of the study were
included for analysis . Out-of-hospital events were defined as
events that began outside a hospital (i.e., initiation of symp-
toms), regardless of the location in which the patient was
eventually pronounced dead .
For purposes of analysis, the initiation of noninstanta-
neous arrhythmic death was considered to be at the onset of
acute symptoms . For example, if a subject who experienced
palpitation at 7 :59 AM, lost consciousness at 8 :07 AM and was
pronounced dead at 9:05 AM, the event was considered to
have begun between 7 :00 and 8:00 AM. Subjects with no
information about the time of the terminal event were
excluded from analysis . Subjects were considered to be
receiving a medication if they were noted to be taking it
regularly at the time of their most recent clinic visit .
Statistical methods. The distribution of the onset of
symptoms was tested against the uniform distribution using
a chi-square goodness of fit test on six 4-h blocks . This is
equivalent to testing whether there were any significant
differences among the numbers of events in the various
blocks. Before looking at the data, we decided to divide the
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Figure 1 . Tinning of event onset (24-h clock) in
the active treatment group . For those events
where only a range of time was known, the
weight of the event was spread uniformly over
the appropriate time . For example, if a patient
was known to have died between 7 :00 Am and
noon, his or her death contributed 0 .20 to each of
the 5 h in that interval .
day into 6-h intervals, beginning at midnight (i .e ., midnight
to 6 AM, 6 AM to noon, noon to 6 PM and 6 PM to midnight) .
To test whether the distribution was uniform over the
daytime hours, the 1st 6 h (midnight to 6 AM) were deleted,
and the chi-square goodness of fit test was used for the
remaining 6-h intervals . These tests were repeated for 4-h
intervals (midnight to 4 AM, 4 AM to 8 AM, 8 AM to noon,
noon to 4 PM, 4 Pm to 8 PM and 8 PM to midnight) to confirm
that our conclusions with regard to the deviation from the
uniform distribution were not based on the selection of
particular time blocks .
For those events where only a range of time was known,
the weight of the event was spread uniformly over the
appropriate time . For example, if a patient was known to
have died between 7:00 Am and noon, his or her death
contributed 0.20 to each of the 5 h between 7 :00 Am and
noon. Throughout this analysis, two-sided p values were
used; and they were considered significant when p < 0.05 .
We also analyzed whether the times after awakening were
uniformly distributed . The time of onset of symptoms was
standardized with respect to the time that the patient awoke
on the day of the death . Chi-square goodness of fit tests were
performed with both 4- and 6-h blocks .
Results
Patients and events . A total of 3,549 patients were en-
rolled in CAST, including the open label and blinded phases
of the study. Overall, there were 219 out-of-hospital arrhyth-
mic deaths/cardiac arrests . In 49 (22%), the time of onset of
symptoms was either unknown or could not be determined
to have occurred within a range <12 h, and these patients
were excluded from analysis. Twenty-five of these patients
were receiving beta-blockers and are considered as a sepa-
rate group . The primary analysis of this study is based on the
95 patients who were receiving active CAST medication at
the time of their event and the 43 who were receiving
placebo or no antiarrhythmic drugs (the CAST medication
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having been discontinued) . Five patients were receiving
another antiarrhythmic drug (the CAST medication having
been discontinued) at the discretion of their referring physi-
cian and were excluded from this analysis .
Temporal distribution of events. Figure 1 shows the event
onset in the 95 patients receiving active CAST medication
(but no beta-blockers) . There is a prominent peak in mid-
morning (6 :00 AM to noon) and another in early evening . The
distribution pattern was similar for all three study drugs, so
they are considered, for purposes of analysis, as a single
group. The temporal distribution of event onset is nonuni-
form when the events are divided into 4-h (p = 0 .002) or 6-h
intervals (p = 0.001). When only "daytime" hours are
considered (omitting the hours between midnight and
6:00 AM), the distribution is significantly nonuniform using
the 6-h intervals (p = 0 .04) .
Figure 2 shows the temporal distribution of event onset in
the 45 patients receiving placebo or no antiarrhythmic ther-
apy (with the exception of beta-blockers) . There is a con-
spicuous peak in the afternoon, and the distribution is
significantly nonuniform for 4-h (p = 0 .007) and 6-h intervals
(p = 0.006). The distribution remains nonuniform for 6-h
intervals (p < 0 .04) when only daytime hours are examined .
The number of events occurring in the group receiving
beta-blockers was much smaller (25), but the distribution of
event onset did not reach statistical significance for nonuni-
formity of fit for either 4- or 6-h intervals .
Acute symptoms . In the active treatment group, 45 events
(47 .4%) were asymptomatic, and 21 events (22
.1%) were
unwitnessed. A total of 15 (51 .7%) of 29 symptomatic events
were accompanied by anginalike symptoms, and 14 patients
had symptoms suggestive of a primary arrhythmic event
(e .g ., palpitation, dizziness)
. In the placebo group, 21 events
(48%) were asymptomatic, and I I events (25
.6%) wcre
unwitnessed. Five patients had anginalike symptoms, and
five had symptoms suggestive of an arrhythmia
. There were
no significant differences in symptom distribution between
the active treatment and placebo groups .
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Relation to awakening. Figure 3 shows the distribution of
the interval between event onset and the time of awakening
in the 44 patients receiving active CAST medication with
known time of awakening . A prominent peak is seen in the
1st 2 h (13 [30%] of 44) . The distribution is significantly
nonuniform for both 4- and 6-h intervals (p < 0 .001 for both).
In contrast, the distribution of onset of symptoms related to
the time of awakening in the placebo/no antiarrhythmic drug
group reveals a prominent peak at 6 to 10 h (Fig . 4) that is
statistically significant when the 24-h period is divided into
6-h (p = 0.03) but not 4-h intervals (p = 0 .25). There were
only 10 events in the beta-blocker group for which the time
of awakening was known, so statistical analysis was not
performed .
Cl,,[ 11, ,= of active therapy placebo/no
groups . Because of major differences in the timing
of event onset and the relation to awakening between the
active therapy and placebo groups, we compared them in a
number of important characteristics (Table 1) . There is a
significant difference (p < 0 .05) in the prevalence of smok-
ing. There are more present smokers in the placebo group
4.07
Hours
7
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2. Timing of event onset (24-h clock) in
the placebo/no antiarrhy is drug group.
(and more former smokers in the active treatment group) .
Also, a higher proportion of the placebo group had new Q
waves (p = 0.03) .
Effects of as More than 501 'v of patients in each
group were receiving aspirin on a regular basis at the time of
their last clinic visit (Table 1). When these patients are
considered se tely, there are no major differences in the
distribution of events in either the active treatment or
placebo group between those who received aspirin and those
who did not .
Discussion
It has been assumed that the higher incidence of arrhyth-
mic death/cardiac arrest in CAST patients receiving active
study medication was due to a proarrhythmic effect of the
drugs. Previous experience with antiarrhythmic drugs has
suggested that their p hythmic potential is most often
expressed in patients with a previous history of sustained
ventricular tachyarrhythmias or severe left ventricular dys-
function, or both (16-18) . Furthermore, this proarrhyt is
Figure 3. Relation of event onset (24-h clock) to
awakening in the active treatment group .
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Figure 4 . Relation of event onset (24-h clock) to
awakening in the placebo/no antiarrhythmic
drug group .
ow 14
potential is usually expressed within 3 days of initiation of
therapy or dosage change, particularly when drug serum
levels are high .
In contrast, arrhythmic death in CAST occurred in pa-
tients without a previous history of sustained ventricular
arrhythmia . Indeed, most patients described in this analysis
had "responded" clinically to the study drugs . Furthermore,
arrhythmic events were distributed over the entire follow-up
period. These observations suggest that a previously un-
known proarrhythmic effect may be operative .
Timing of events . Examination of the timing of these
events and their relation to awakening may be helpful in
determining the mechanism . Arrhythmic death in the CAST
active treatment group was most prevalent in midmorning,
with a secondary peak in late afternooWearly evening . A
Table 1. Baseline Characteristics of the Active Treatment Group
and the Placebo/No Antiarrhythmic Drug Group, Excluding
Patients Receiving Beta-Adrenergic Blocking Agents
*No information available in three active therapy and five placebo group
patients . CHF = congestive heart failure ; MI = a myocardial infarction that
had occurred before the Cardiac Arrhythmia Suppression Trial-qualifying
infarct .
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similar pattern has been described in previous studies of
sudden cardiac death (5) . In contrast, in the placebo group
there were relatively few events in midmorning and a prom-
inent peak in the afternoon. That these findings are real is
supported by the relation between event onset and awaken-
ing. In the active treatment group, there is a prominent peak
in the I st 2 h after awakening, whereas in the placebo group,
the peak is most prominent at 6 to 10 h . The morning peak
has been previously ascribed to activation of the sympa-
thetic nervous system and its attendant effects on heart rate,
blood pressure, vascular reactivity and other faz-,,-7s (19) .
Relevant to this concept, Myerburg et al. (20) have recently
reported that the beta-blocker propranolol may reverse
potentially lethal ventricular proarrhythmia associated with
the use of encainide or flecainide .
The late afternoon/early evening peak in event frequency
observed in the CAST active treatment group is more typical
of the timing of onset of acute myocardial infarction than of
sudden cardiac death (7,8) . Thus, the adverse effects of the
study drugs may also include a contribution from the effects
of acute myocardial ischemia. This finding is supported by
the fact that there were more non-Q wave (CAST-qualifying)
myocardial infarctions in the active treatment than in the
placebo group. In fact, anginalike symptoms preceded ar-
rhythmic death in the majority of symptomatic events and
were likely to have contributed to a number of the asymp-
tomatic events, given the high prevalence of silent myocar-
dial ischemia . In a recent study of sudden cardiac death
during ambulatory ECG monitoring, Pepine et al . (21) found
that signs of ischemia preceded the terminal event in most of
the patients with interpretable ECGs. Thus, the present
analysis suggests the possibility of a new expression of the
proarrhythmic potential of the study drugs, involving an
interaction among sympathetic nervous system activation,
acute myocardial ischemia and probably other unknown
factors as well .
We are unable to fully explain the distribution of events
Active Treatment
Group
(n = 95)
Placebo Group
(n = 43) p Value
Age (>70 yr)
22 (23 .2%) 11 (25 .69) 0.76
History of CHF 40 (42 .1%) 12 (27.9%) 0.11
History of Ml 61 (64 .2%) 21(48
.8%)
0.09
Male 79 (83 .2%) 34(111%)
0.56
Diabetes
32 (33 .7%) 11 (25,69o') 0.34
Q waves present* 71(73 .5%) 30 (78 .9%) 0.77
New Q waves* 54 (58.7%) 30 P8
.9%x) 0.03
Smoker
Present 25(27.3%)
20 (46 .5%) 0.05
Former
51(53 .7%) 15 (34 .91/) 0.05
Never
19 (20.0%) 8(18 .617o)
0.80
Ejection fraction :-:-4017o 58 (61 .1%) 25(58 .1%)
0.82
Receiving aspirin
54 (56.8%) 29(67 .4%) 0.24
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observed i n the placebo group . Although differing somewhat
from the active treatment group in certain demographic
characteristics, they are probably similar to populations
described in other studies of the circadian distribution of
sudden cardiac death . Because these other studies do not
provide information about antiarrhythmic drug use, it is
possible that the event distributions that they describe might
have been considerably different if patients receiving antiar-
rhythmic drugs had been excluded. The issue of antiarrhyth-
mic drugs, especially those with conduction-slowing proper-
ties, must be taken into account in designing future trials .
The pathogenesis of afternoon and early evening peaks in
acute cardiac events in general is unclear . We speculate that
some factors may be fatigue associated with the end of the
workday, the coming together of the family unit and stress
associated with the evening meal, traditionally the heaviest
and most complicated, as well as the one with the greatest fat
content. Anginalike symptoms preceded the event in half of
the symptomatic arrhythmic deaths in the placebo group,
suggesting that myocardial ischemia may be playing a role .
e . Because of the potential importance of our
findings, further consideration of our methodology is war-
ranted. In common with previous studies, our primary
hypothesis was designed to assess those events that began
outside the hospital . Patients in the hospital are subject to a
variety of circumstances (e .g., being awakened at 2 :00 AM to
receive medication or have vital signs taken) that may
interrupt the normal wake-sleep cycle and interfere with
circadian rhythms . In addition, premonitory events that
might progress to fatal arrhythmias outside the hospital often
respond to medical intervention in patients in the hospital .
The CAST definition of arrhythmic death differs slightly
from those used in some other studies in that it included
resuscitated cardiac arrest . Resuscitated cardiac arrest was
included as a primary end point in CAST because it was
considered that the outcome of a resuscitation may depend
as much on where it occurred (e .g., accessibility to people
trained to perform cardiopulmonary resuscitation) as on how
it occurred .
Because of similarities in protocol and in the results with
the three study drugs, we chose to combine the patients
receiving those drugs into a single group
. Similarly, we
grouped together patients taking placebo and those who
were taking no antiarrhythmic drugs at the time of their
event, regardless of whether they had originally been ran-
domized to receive placebo or active treatment . We also
chose to analyze events from all parts of the stud;' (open
label titration, blinded titration, randomized double-blinded
follow-up phase) because we considered that the patient's
medication status at the time of the event was more im-
portant than the phase of the study in which the event
occurred.
Study limitations. A major limitation of the present study
is the lack of a true control group. Arrhythmic death in
CAST was not a random event, so it would not be expected
that all of the baseline characteristics of the patients expe-
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riencing this event would be similar in our active treatment
and placebo groups ; in fact, differences do exist, Another
limitation is the unexpected absence of a midmorning peak in
the latter group . However, this study was planned prospec-
tively to determine whether antiarrhythmic drugs would
alter the temporal distribution of arrhythmic death, and the
value of our findings is not necessarily diminished by the
results in patients not taking these drugs . Another potential
limitation is that patients who were intolerant of all study
drugs or who chose to drop out of the trial before random-
ization were excluded from analysis, thus potentially influ-
encing our results .
Finally, although we were able o obtain the time of event
onset in almost 80% of cases, the time of awakening could be
determined in only 45%. Because this is not a random
sample of our overall population, the validity of our obser-
vations with regard to the time of awakening will require
confirmation by future trials .
Conclusions . Out-of-hospital arrhythmic death/cardiac
arrest in the CAST active treatment group displayed a
bimodal variation with peaks in mid to late morning and late
afternoon/early evening. More than half of the symptomatic
events were accompanied by anginalike symptoms. Approx-
imately 30°%O of all events occurred within 2 h of awakening .
Our data suggest the possibility of a complex mechanism
involving an interaction among the study drugs, sympathetic
nervous system activation and acute ischemia . Arrhythmic
death/cardiac arrest in the CAST patients taking placebo or
no antiarrhythmic drugs displayed a prominent afternoon
peak of unknown pathogenesis . Planning of future clinical
trials will need to take this information into account .
References
I . The CAST Investigators . Preliminary report : effect of r:cainide and
flecainide on mortality in a randomized trial of arrhythmia suppression
after myocardial infarction . N Engl J Med 1989 ;321 :406-12.
2 . Echt DS, Liebson PR, Mitchell B, et al. and the CAST Investigators .
Mortality and morbidity in patients receiving encainide, flecainide or
placebo: the Cardiac Arrhythmia Suppression Trial . N Engl J Med
1991 ;324 :781-88.
3. The CAST Investigators . Effect of the antiarrhythmic agent moricizine on
survival after myocardial infarction. N Engl J Med 1992 ;327 :227-33 .
4. Muller JE, Ludmer PL, Willich SN, et al . Circadian variation in the
frequency of sudden cardiac death. Circulation 1987 ;75 :131-8 .
5. Willich SN, Levy D. Rocco MB, Tofler GH, Stone PH, Muller JE .
Circadian variation in the ictcidence of sudden cardiac death in the
Framingham Heart Study population . Am J Cardiol 1987 ;60:801-6 .
6. Peters RW, MullerJE, Goldstein S, Byington R, Friedman L . Propranolol
and the morning increase sudden cardiac death (BRAT study). Am J
Cardiol 1989;63 :1518-20 .
7 . Muller JE, Stone PH, Turi ZG, et al . and the MILLS Study Group .
Circadian variation in the frequency of onset of acute myocardial infarc-
tion . N Engl J Med 1985 ;313 :1315-22.
8. Hjalmarson A, Gilpin EA, Nicod P, et al . Differing circadian patterns of
symptom onset in subgroups of patients with acute myocardial infarction .
Circulation 199919.267-75 .
9 . Rocco MB, Barry J, Campbell S, et al . Circadian variation of transient
myocardial ischemia in patients with coronary artery disease . Circulation
1987;75:395-401 .
10. Mulcahy D, Cunningham D, Crean P, et al
. Circadian variation of total
JACC Vol . 23, No . 2
February 1994:283-9
ischemic burden and its alteration with antianginal agents . Lancet 1988;
2 :755-89 .
11
. Marler JR, Price TR, Clark GL, et al . Morning increase in onset of
ischemic stroke. Stroke 1989 ;20:473-6.
12 . Colantonio D, Casale R, Abruzzo BP, Lorenzetti G, Pasqualetti P
.
Circadian distribution in fatal pulmonary thromboembolism . Am I Cardiol
1989 ;64 :403-4.
13
. Goldberg RJ, Brandy P, Muller 1E, et al . Time of onset of symptoms of
acute myocardial infarction
. Am J Cardiol 1990,66 :140-4 .
14
. Willich SN, Goldberg RJ, Maclure M . Perriello L, Muller JE . Increased
onset of sudden cardiac death in the first 3 hours after awakening
. Am J
Cardiol 1992 ;70:65-8 .
15 . Greene HL, Richardson DW, Barker AEI, et al . and the CAPS Investi-
gators
. Classification of deaths after myocardial infarction as arrhythmia
or nonarrhythmic (the Cardiac Arrhythmia Pilot Study) . Am J Cardiol
1989,63 :1-6 .
16. Podrid PJ, Lampert S, Graboys TB, Blatt CM, Lown B
. Aggravation of
PETERS ET AL .
	
289
CIRCADIAN PATTERN OF ARRHYTHMIC DEATH IN CAST
arrhythmia by antiarrhythmic drugs
: incidence and predictor
. Am J
Cardiol 1987 ;59:38E. 44E .
17 . Stanton MS, Pryslowsky EN, Fineberg NS, Miles WM, Zipes DP . Heger
JJ
. Arrhythmogenic effects of antiarrhythmic drugs : a study of 506
patients treated for ventricular tachycardia or fibrillation . J Am Coll
Cardiol 1989;14 :209-15 .
18 . Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN . Clinical
characteristics of patients with ventricular fibrillation during antiarrhyth-
mic drug therapy . N Engl J Med 1988 ;319 :257-62.
19 . Muller JE, Tofler GH, Stone PH . Circadian variation and triggers of onset
of acute cardiovascular disease
. Circulation 1989 ;79:733-43 .
20 . Myerburg RJ, Kessler KM, Cox MM, et al . Reversal of proarrhythmic
effects of flecainide acetate and encainide hydrochloride by propranolol .
Circulation 1989 ;80 :1571-9.
21 . Pepine CJ, Morganroth J, McDonald JT, Gottlieb SO . Sudden death
during ambulatory electrocardiographic monitoring . Am J Cardiol 1991 ;
68 :785-8 .
